WHAT IS ALREADY KNOWN ON THIS TOPICCancer can be controlled by T cells that recognize tumor antigens. Checkpoint immunotherapy increases the effectiveness of T cells in controlling cancer by restoring function to exhausted T cells. In a significant fraction of patients, immunotherapy is not successful, most likely because there are not a sufficient number of T cells that target tumor antigens. Dendritic cells present tumor antigen epitopes to T cells on major histocompatibility complex class I but may not activate a sufficient number of antitumor T cells. Therapeutic dendritic cell vaccines that present tumor antigen to T cells have seen some clinical success. Lentiviral vectors provide a means to achieve long-term expression of transgenes by virtue of their ability to integrate into the host cell chromosome.
And about time! Greetings from Heathrow, VN fans.